- Home
- PULM vs PCLA Comparison
PULM vs PCLA Comparison
Compare PULM & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- PCLA
- Stock Information
- Founded
- PULM 2003
- PCLA 2008
- Country
- PULM United States
- PCLA Japan
- Employees
- PULM N/A
- PCLA N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- PCLA Building Products
- Sector
- PULM Health Care
- PCLA Consumer Discretionary
- Exchange
- PULM Nasdaq
- PCLA Nasdaq
- Market Cap
- PULM 20.5M
- PCLA 71.3M
- IPO Year
- PULM N/A
- PCLA 2025
- Fundamental
- Price
- PULM $5.48
- PCLA $0.49
- Analyst Decision
- PULM
- PCLA
- Analyst Count
- PULM 0
- PCLA 0
- Target Price
- PULM N/A
- PCLA N/A
- AVG Volume (30 Days)
- PULM 11.7K
- PCLA 4.0M
- Earning Date
- PULM 08-12-2025
- PCLA 01-01-0001
- Dividend Yield
- PULM N/A
- PCLA N/A
- EPS Growth
- PULM N/A
- PCLA N/A
- EPS
- PULM N/A
- PCLA N/A
- Revenue
- PULM $1,921,000.00
- PCLA $5,475,228.00
- Revenue This Year
- PULM N/A
- PCLA N/A
- Revenue Next Year
- PULM $134.88
- PCLA N/A
- P/E Ratio
- PULM N/A
- PCLA N/A
- Revenue Growth
- PULM N/A
- PCLA 40.19
- 52 Week Low
- PULM $1.78
- PCLA $0.37
- 52 Week High
- PULM $10.40
- PCLA $9.80
- Technical
- Relative Strength Index (RSI)
- PULM 28.72
- PCLA N/A
- Support Level
- PULM $5.60
- PCLA N/A
- Resistance Level
- PULM $6.15
- PCLA N/A
- Average True Range (ATR)
- PULM 0.29
- PCLA 0.00
- MACD
- PULM -0.08
- PCLA 0.00
- Stochastic Oscillator
- PULM 4.29
- PCLA 0.00
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.